# A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)

> **NCT07227311** · PHASE2 · RECRUITING · sponsor: **GlaxoSmithKline** · enrollment: 200 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Belantamab mafodotin
- **DRUG:** Dexamethasone
- **DRUG:** Pomalidomide
- **DRUG:** Bortezomib
- **DRUG:** Carfilzomib

## Key facts

- **NCT ID:** NCT07227311
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-15
- **Primary completion:** 2030-08-30
- **Final completion:** 2030-08-30
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2026-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07227311

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07227311, "A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT07227311. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*